{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"71.0","value":"37.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Progression-free Survival was defined as documented PD, or death of any cause. Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Plitidepsin was to be administered as a 3-hour (h) intravenous (i.v.) infusion at a dose of 5 mg/m2, on Day (D) 1 and 15, every four weeks (q4wk); BTZ was to be administered as a subcutaneous (s.c.) injection at a dose of 1.3 mg/m2 on D1, 4, 8 and 11, q4wk and DXM was to be taken orally at a dose of 40 mg/day on D1, 8, 15 and 22, q4wk. A cycle was defined as 28 days, plus any additional days required for dosing delays due to any reason. Treatment cycles were repeated q4wk.","id":"OG000","title":"Experimental"}],"paramType":"NUMBER","populationDescription":"1 died without any valid tumor assessment done\n\n1 discontinued treatment-related AEs","reportingStatus":"POSTED","timeFrame":"From the date of first drug administration to the date of documented PD, or death (of any cause), up to 3 months","title":"Percentage of Participants With Progression-free Survival at 3 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}